Gene Expression Signatures for Sepsis Mortality Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating sepsis lack accuracy in predicting mortality and identifying at-risk patients, relying on clinical severity scores and biomarkers that do not adequately quantify the patient's dysregulated immune response.
Innovation Solution
Development of gene expression-based methods that measure differential expression of specific genes in whole-blood samples using platforms like PCR, sequencing, and hybridization to identify gene signatures associated with increased mortality risk, enabling the development of systems for predicting sepsis and ventilator-associated pneumonia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical severity scores and traditional biomarkers are used for diagnosing sepsis, then the diagnostic process is simple and quick, but the accuracy in predicting mortality and identifying at-risk patients is insufficient
Solution Approach 1:
The patent segments the complex immune response into specific gene expression signatures (e.g., upregulation of TRIB1, CKS2, MKI67, POLD3, PLK1 and downregulation of TGFBI, LY86, CST3, CBFA2T3, RCBTB2, TST, CX3CR1, CD5, MTMR11, CLEC10A, EMR3, DHRS7B, CEACAM8). By dividing the overall immune response into discrete, measurable gene markers, the system achieves precise mortality prediction while maintaining operational feasibility through targeted measurement rather than complete transcriptomic analysis.
Solution Approach 2:
The patent transitions from traditional two-dimensional diagnostic approaches (clinical scores and a few biomarkers) to a high-dimensional transcriptomic approach. By measuring expression levels of multiple genes simultaneously in whole-blood samples, the system captures the complex, multi-faceted nature of sepsis pathophysiology, enabling significantly improved mortality prediction accuracy that cannot be achieved with conventional single-biomarker or clinical-score-based methods.
2Reliability
If whole-blood transcriptomic profiling is performed to stratify sepsis patients, then the accuracy in predicting outcomes is improved, but the cost and complexity of implementation increase
Solution Approach 1:
The patent extracts and focuses on a specific subset of genes (15 upregulated and 13 downregulated genes) from the entire transcriptome. Rather than requiring comprehensive whole-transcriptome sequencing, the system isolates and measures only the most prognostically relevant genes, thereby achieving reliable prognosis accuracy while reducing the complexity and cost of implementation. This selective gene panel approach makes the technology more clinically feasible.
Solution Approach 2:
The patent applies partial action by measuring only the specific genes known to be differentially expressed in sepsis, rather than performing complete transcriptomic profiling. This partial measurement approach (focusing on a curated panel of 28 genes) provides sufficient prognostic information for reliable stratification while avoiding the excessive complexity and cost of analyzing the entire genome-wide expression profile.
3Adaptability or versatility
If high-dimensional transcriptomic data is analyzed to address heterogeneous representations of sepsis, then the ability to answer research questions across different patient types is improved, but the difficulty of data processing and translation to clinical practice increases
Solution Approach 1:
The patent applies local quality by focusing measurement and analysis on specific genes with known prognostic relevance rather than treating the entire transcriptome uniformly. By identifying and measuring only the locally relevant genes (TRIB1, CKS2, MKI67, etc.) that are differentially expressed in sepsis, the system achieves versatile applicability across different patient types while simplifying data processing. This targeted approach makes the complex high-dimensional data more manageable and easier to translate to clinical practice.
Data Source
AI summary
The present disclosure provides methods for determining whether a subject has sepsis, or is at risk of developing sepsis, and methods of treating the subject based on the determination. Also provided are methods for determining an increased risk of mortality in a subject with sepsis or suspected of having sepsis, and methods of treating the subject based on the determination. Systems useful for the same are also provided.